Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.

ABSTRACT:

Background

Definite prognostic clinical factors of benefit for decitabine-based induction chemotherapy in elderly patients newly diagnosed with acute myeloid leukaemia (AML) are not identified. This study was designed to explore the potential biomarker, especially regeneration of haematopoiesis, of treatment response and survival in elderly patients with newly diagnosed AML.

Method

We analysed the clinical data of 117 elderly AML patients who were treated with a decitabine dose of 15 mg/m² for 5 days, granulocyte colony-stimulating factor of 300 μg/d for priming, plus cytarabine 10 mg/m² q12h for 7 days and aclarubicin 10 mg/d for 4 days (D-CAG).

Results

After initial induction chemotherapy, the overall response rate and complete remission (CR) w

SUBMITTER: Huang J 

PROVIDER: S-EPMC6299938 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature